2. Search Result
Search Result
Results for "

dopamine levels

" in MedChemExpress (MCE) Product Catalog:

48

Inhibitors & Agonists

1

Biochemical Assay Reagents

3

Peptides

8

Natural
Products

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-42849A
    Sultopride hydrochloride
    1 Publications Verification

    LIN-1418 hydrochloride

    		 Dopamine Receptor Neurological Disease
    Sultopride hydrochloride (LIN-1418 hydrochloride) is a selective antagonist of dopamine D2 receptor.
    Sultopride hydrochloride
  • HY-12713
    Lisuride

    		Dopamine Receptor Neurological Disease
    Lisuride is an orally active dopamine D2 receptors agonist. Lisuride, as an ergot derivative, can be used for the research of Parkinson's disease, migraine, and high prolactin levels .
    Lisuride
  • HY-113257
    Dopamine 4-sulfate

    DA-4S; dopamine 4-Sulfate

    		 Drug Metabolite Neurological Disease
    Dopamine 4-sulfate (DA-4S) is an inactive metabolite of the catecholamine dopamine. It is formed from dopamine by the sulfotransferase (SULT) isoform SULT1A3. Dopamine 4-O-sulfate is found at lower levels in the brain and circulation than dopamine 3-O-sulfate.
    Dopamine 4-sulfate
  • HY-115968
    Dopamine D3 receptor ligand-4

    		Dopamine Receptor Neurological Disease
    Dopamine D3 receptor ligand-4 (compound 6) is a potent and selective dopamine D3 receptor ligand, with a Ki of 0.5 nM. Dopamine D3 receptor ligand-4 shows high level of selectivity for D3 over D2 (Ki=7.43 nM) .
    Dopamine D3 receptor ligand-4
  • HY-W845607
    Milacemide

    		Monoamine Oxidase Neurological Disease
    Milacemide, a glycinamide derivative, is an orally active MAO-B inhibitor with anticonvulsant activity. Milacemide reduces the levels of dihydroxyphenylacetic acid and homovanilic acid, but increases the levels of dopamine and serotonin in the caudate nucleus. Milacemide is promising for research of Alzheimer's disease .
    Milacemide
  • HY-N5126
    Juncusol

    		Others Neurological Disease
    Juncusol, a phenanthrenoid found in Juncus setchuenensis, possesses anxiolytic effect. Juncusol is associated with metabolic changes in cortical serotonin/dopamine levels in Mice .
    Juncusol
  • HY-130205
    Milacemide hydrochloride

    CP 1552 S

    		 Monoamine Oxidase Neurological Disease
    Milacemide hydrochloride (CP 1552 S), a glycinamide derivative, is an orally active MAO-B inhibitor with anticonvulsant activity. Milacemide hydrochloride reduces the levels of dihydroxyphenylacetic acid and homovanilic acid, but increases the levels of dopamine and serotonin in the caudate nucleus. Milacemide hydrochloride is promising for research of Alzheimer's disease .
    Milacemide hydrochloride
  • HY-42849
    Sultopride

    LIN-1418

    		 Dopamine Receptor Neurological Disease
    Sultopride (LIN-1418) is a selective antagonist of dopamine D2 receptor.
    Sultopride
  • HY-42849AR
    Sultopride hydrochloride (Standard)

    		Dopamine Receptor Neurological Disease
    Sultopride hydrochloride (Standard) is the analytical standard of Sultopride hydrochloride. This product is intended for research and analytical applications. Sultopride hydrochloride (LIN-1418 hydrochloride) is a selective antagonist of dopamine D2 receptor.
    Sultopride hydrochloride (Standard)
  • HY-N3550
    Catalponol

    		Others Cancer
    Catalponol is a naphthoquinone derivative. Catalponol enhances dopamine biosynthesis by inducing tyrosine hydroxylase activity. Catalponol also increases the levels of cAMP and tyrosine hydroxylase phosphorylation in PC12 cells .
    Catalponol
  • HY-117902
    SRI-31142

    		Dopamine Transporter Neurological Disease
    SRI-31142 is a putative, brain-penetrant allosteric inhibitor of the dopamine transporter (DAT). In behavioral studies using intracranial self-stimulation (ICSS), SRI-31142 did not produce the abuse-related effects seen with cocaine and GBR-12935, but instead reduced ICSS responses and dopamine levels in the nucleus accumbens (NAc) at effective doses. SRI-31142 also blocked cocaine-induced increases in ICSS and NAc dopamine .
    SRI-31142
  • HY-W423643
    Benzedrone

    4-Methyl-N-benzylcathinone

    		 Drug Derivative Neurological Disease
    Benzedrone is a synthetic cathinone derivative. Benzedrone can increase the levels of neurotransmitters such as dopamine, serotonin and norepinephrine in the brain, thus producing a stimulant effect. Benzedrone can be used in the research of new psychoactive substances (NPS) .
    Benzedrone
  • HY-116062
    JNJ-7925476 hydrochloride

    		Monoamine Transporter Dopamine Transporter Adrenergic Receptor Others
    JNJ-7925476 (hydrochloride) is a triple monoamine uptake inhibitor with the ability to regulate neurotransmitter levels and antidepressant activity. JNJ-7925476 (hydrochloride) can be rapidly absorbed into the plasma in rats, with a higher concentration in the brain than in plasma. It can induce an increase in the levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex, and exhibits antidepressant activity in the mouse tail suspension test.
    JNJ-7925476 hydrochloride
  • HY-E70007
    Catechol O-methyltransferase, porcine liver

    COMT

    		 Endogenous Metabolite Neurological Disease
    Catechol O-methyltransferase, porcine liver (COMT), the magnesium-dependent transfer of methyl groups from S-adenosyl methionine to a hydroxyl group on dopamine, converting it to 3-methoxytyramine. Catechol O-methyltransferase has two forms in tissues, a soluble form (S-COMT) and a membrane-bound form (MB-COMT). Catechol O-methyltransferase is to regulate epinephrine, norepinephrine, and dopamine levels in the brain .
    Catechol O-methyltransferase, porcine liver
  • HY-116507
    AZD0328

    		nAChR Neurological Disease
    AZD0328 is a selective α7 nAChR partial agonist. AZD0328 selectively enhances midbrain dopaminergic neuronal activity and enhances cortical dopamine levels in rats. AZD0328 improves cognitive performance .
    AZD0328
  • HY-W049881
    9-Methyl-β-carboline

    		Dopamine Receptor Neurological Disease Inflammation/Immunology
    9-Methyl-β-carboline is a cognitive enhancer with neuroprotective, neurorestorative and anti-inflammatory properties. The behavioral effects of 9-Methyl-β-carboline may be related to the stimulation of hippocampal dopamine levels and dendritic and synaptic proliferation .
    9-Methyl-β-carboline
  • HY-W250174
    Lithium 3,5-diiodosalicylate

    3,5-Diiodosalicylic acid lithium salt

    		 Biochemical Assay Reagents Others
    Lithium 3,5-diiodosalicylate is a compound used in the study of bipolar disorder and other psychiatric disorders. It contains lithium and a salicylate. Lithium 3,5-diiodosalicylate works by affecting the levels of certain neurotransmitters in the brain, including dopamine and serotonin.
    Lithium 3,5-diiodosalicylate
  • HY-120017
    Befloxatone

    MD-370503

    		 Monoamine Oxidase Neurological Disease
    Befloxatone (MD-370503) is an orally active, selective and reversible inhibitor of Monoamine Oxidase A (MAO-A) (IC50=4 nM). Befloxatone increases the tissue level of monoamine, striatal dopamine and cortical norepinephrine. Befloxatone has antidepressant potential .
    Befloxatone
  • HY-151094
    FTEAA

    		Monoamine Oxidase Neurological Disease
    FTEAA is a 4-styrylpiperidine inhibitor. FTEAA exhibits potent inhibitory effect towards both monoamine oxidase with IC50s of 0.52 μM (MAO-A), 1.02 μM (MAO-B), respectively. MAO inhibitors can be used for cardiovascular, neurological and oncological disorders research .
    FTEAA
  • HY-P1329
    CTOP

    		Opioid Receptor Neurological Disease
    CTOP is a potent and highly selective μ-opioid receptor antagonist. CTOP antagonizes the acute morphine-induced analgesic effect and hypermotility. CTOP enhances extracellular dopamine levels in the nucleus accumbens. CTOP dose-dependently enhances locomotor activity .
    CTOP
  • HY-115447
    Clobenpropit

    		Histamine Receptor Neurological Disease
    Clobenpropit is a potent histamine H3-receptor antagonist. Clobenpropit decreases dopamine release and increases histamine levels in the hypothalamus. Clobenpropit shows antipsychotic-like activities. Clobenpropit causes a resuscitating effect in rats subjected to the hemorrhagic shock .
    Clobenpropit
  • HY-13736A
    Quinagolide hydrochloride

    CV205-502 hydrochloride

    		 Dopamine Receptor Akt Neurological Disease Cancer
    Quinagolide hydrochloride (CV205-502 hydrochloride) is a selective and orally active dopamine D2 receptor agonist. Quinagolide hydrochloride is an inhibitor of prolactin. Quinagolide hydrochloride down-regulates AKT levels and its phosphorylation. Quinagolide hydrochloride shows antitumor effects, it can be used for the research of cancer .
    Quinagolide hydrochloride
  • HY-P10435
    KEMPFPKYPVEP

    		Dopamine Receptor Neurological Disease
    KEMPFPKYPVEP is a 12-amino acids neuropeptide, which upregulates levels of dopamine (DA) and norepinephrine (NE) in the prefrontal cortex, exhibits spatial and object recognition memory promoting ability in Scopolamine (HY-N0296)-induced amnesia mouse model .
    KEMPFPKYPVEP
  • HY-P1329A
    CTOP TFA
    1 Publications Verification

    		 Opioid Receptor Neurological Disease
    CTOP TFA is a potent and highly selective μ-opioid receptor antagonist. CTOP TFA antagonizes the acute analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances locomotor activity .
    CTOP TFA
  • HY-107055
    RTI 336

    		Dopamine Transporter Neurological Disease
    RTI 336 is a phenyltropane analog, as well as a potent and selective dopamine transporter (DAT) inhibitor. RTI 336 inhibits addictive agent induced locomotor activity and self-administration in Lewis rats. RTI 336 exhibits inhibitory effects depending on inherent NAc DAT levels .
    RTI 336
  • HY-W116433
    SK609

    		Dopamine Receptor Neurological Disease
    SK609 is a selective dopamine D3 receptor agonist with activity that improves dopamine and norepinephrine levels in the cerebral cortex. SK609 has been successfully used to suppress dyskinesias in Parkinson's disease models and alleviated muscle twitches induced by L-dopa. SK609 improved performance in sustained attention tasks by significantly reducing misses and false alarms. SK609 may provide an inhibitory option for suppressing movement and cognitive impairment in patients with Parkinson's disease .
    SK609
  • HY-N1420
    Rhamnose

    L-Rhamnose

    		 Endogenous Metabolite MMP Interleukin Related PKA Infection Metabolic Disease Cancer
    Rhamnose (L-Rhamnose ) is an orally active deoxysugar. Rhamnose can inhibit levels of pro-inflammatory interleukin and matrix metalloproteinases (MMPs) in skin aging models. Rhamnose can promote the phosphorylation levels of PKA substrates and HSL in SVF-derived adipocytes, stimulating PKA signaling. Rhamnose can act against obesity in mice by stimulating fat dopamine receptors and inducing thermogenesis. Rhamnose shows anti-aging effects. Rhamnose monohydrate can be used in the study of Ehrlich’s solid tumors and sarcomas .
    Rhamnose
  • HY-N1420A
    Rhamnose monohydrate

    L-Rhamnose monohydrate

    		 Endogenous Metabolite MMP Interleukin Related PKA Infection Metabolic Disease Cancer
    Rhamnose monohydrate (L-Rhamnose monohydrate) is an orally active deoxysugar. Rhamnose monohydrate can inhibit levels of pro-inflammatory interleukin and matrix metalloproteinases (MMPs) in skin aging models. Rhamnose can promote the phosphorylation levels of PKA substrates and HSL in SVF-derived adipocytes, stimulating PKA signaling. Rhamnose monohydrate can act against obesity in mice by stimulating fat dopamine receptors and inducing thermogenesis. Rhamnose monohydrate shows anti-aging effects. Rhamnose monohydrate can be used in the study of Ehrlich’s solid tumors and sarcomas .
    Rhamnose monohydrate
  • HY-162760
    COMT-IN-1

    		COMT Monoamine Oxidase Neurological Disease
    COMT-IN-1 (compound C12), a nitrophenolic analogue, is an orally active dopamine metabolic enzyme catechol-O-methyltransferase (COMT) inhibitor with IC50s of 0.37 μM, 95.58 μM and 58.82 μM for COMT, MAO-A and MAO-B, respectively. COMT-IN-1 exhibits chelation with a variety of metal ions. COMT-IN-1 exhibits good BBB permeability. COMT-IN-1 improves dopamine levels and ameliorates MPTP (HY-15608)-induced Parkinson's disease (PD) symptoms in mice .
    COMT-IN-1
  • HY-W704749
    7-Hydroxychlorpromazine hydrochloride

    		Drug Metabolite Dopamine Receptor Neurological Disease
    7-Hydroxychlorpromazine hydrochloride is the active metabolite of Chlorpromazine (HY-12708). 7-Hydroxychlorpromazine hydrochloride can increase prolactin levels in rats. 7-Hydroxychlorpromazine hydrochloride can increase dopamine turnover and has a sedative effect. In addition, 7-Hydroxychlorpromazine hydrochloride can effectively inhibit amphetamine-induced stereotyped behavior in rats and is used in the study of psychosis .
    7-Hydroxychlorpromazine hydrochloride
  • HY-13340
    VU0152100

    VU152100

    		 mAChR Neurological Disease
    VU0152100 (VU152100) is a highly selective mAChR positive allosteric modulator (permeable to the blood-brain barrier). VU0152100 reverses Amphetamine-induced hypermotility in rats and increased levels of extracellular dopamine in nucleus accumbens and caudate-putamen. VU0152100 has good research potential in psychosis and cognitive impairment associated with mental disorders such as schizophrenia .
    VU0152100
  • HY-N1420AR
    Rhamnose monohydrate (Standard)

    L-Rhamnose monohydrate (Standard)

    		 Reference Standards Endogenous Metabolite MMP Interleukin Related PKA Infection Metabolic Disease Cancer
    Rhamnose monohydrate (Standard) is the analytical standard of Rhamnose monohydrate (HY-N1420A). Rhamnose monohydrate (L-Rhamnose monohydrate) is an orally active deoxysugar. Rhamnose monohydrate can inhibit levels of pro-inflammatory interleukin and matrix metalloproteinases (MMPs) in skin aging models. Rhamnose can promote the phosphorylation levels of PKA substrates and HSL in SVF-derived adipocytes, stimulating PKA signaling. Rhamnose monohydrate can act against obesity in mice by stimulating fat dopamine receptors and inducing thermogenesis. Rhamnose monohydrate shows anti-aging effects. Rhamnose monohydrate can be used in the study of Ehrlich’s solid tumors and sarcomas .
    Rhamnose monohydrate (Standard)
  • HY-B1371
    Spiperone
    2 Publications Verification

    Spiroperidol

    		 Dopamine Receptor 5-HT Receptor Wnt Neurological Disease
    Spiperone (Spiroperidol) is a potent dopamine D2, serotonin 5-HT1A, and serotonin 5-HT2A antagonist. Spiperone is also a labelled ligand for neuroleptic receptors. Spiperone enhances intracellular calcium level and inhibits the Wnt signaling pathway. Spiperone has the potential for the research of neurology diseases .
    Spiperone
  • HY-111066
    JNJ-37822681

    		Dopamine Receptor Others
    JNJ-37822681 is a fast dissociating D2 antagonist with activity in inhibiting schizophrenia. JNJ-37822681 has high specificity for D2 receptors and is effective in animal models, inducing increased levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex, and exhibiting antidepressant activity in the mouse tail suspension test, while having a good brain distribution and lower prolactin release.
    JNJ-37822681
  • HY-12363
    U-69593

    		Opioid Receptor Neurological Disease
    U-69593 is a potent and selective κ1-opioid receptor agonist . U-69593 attenuates addictive agent-induced behavioral sensitization in the rat . U-69593 reduces anxiety and enhances spontaneous alternation memory in mice . U-69593 reduces calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum .
    U-69593
  • HY-W417914
    4-Methylamphetamine hydrochloride

    4-MA hydrochloride

    		 5-HT Receptor Monoamine Transporter Dopamine Receptor Neurological Disease
    4-Methylamphetamine hydrochloride is a 5-HT1A receptor agonist that induces hypothermia in rats by binding to the 5-HT1A receptor. Additionally, 4-Methylamphetamine hydrochloride acts on norepinephrine (NE), dopamine (DA), and serotonin (5-HT) transporters to increase the extracellular levels of these neurotransmitters. 4-Methylamphetamine hydrochloride can be used in the study of neurological disorders .
    4-Methylamphetamine hydrochloride
  • HY-124357
    Seproxetine hydrochloride

    S-Norfluoxetine hydrochloride; LY 215229 hydrochloride

    		 Dopamine Receptor Neurological Disease
    Seproxetine (S-Norfluoxetine) hydrochloride is a selective serotonin reuptake inhibitor (SSRI) that enhances serotonin levels in the brain by specifically inhibiting the serotonin uptake carrier. Seproxetine hydrochloride exhibits strong charge transfer interactions with π-electron acceptors, forming stable complexes that enhance its binding affinity to multiple receptors, including serotonin and dopamine receptors. Seproxetine hydrochloride demonstrates improved biological activity when interacting with charge transfer complexes, leading to increased stability and efficacy in therapeutic applications.
    Seproxetine hydrochloride
  • HY-B1371R
    Spiperone (Standard)

    		Dopamine Receptor 5-HT Receptor Wnt Neurological Disease
    Spiperone (Standard) is the analytical standard of Spiperone. This product is intended for research and analytical applications. Spiperone (Spiroperidol) is a potent dopamine D2, serotonin 5-HT1A, and serotonin 5-HT2A antagonist. Spiperone is also a labelled ligand for neuroleptic receptors. Spiperone enhances intracellular calcium level and inhibits the Wnt signaling pathway. Spiperone has the potential for the research of neurology diseases .
    Spiperone (Standard)
  • HY-13340R
    VU0152100 (Standard)

    		mAChR Neurological Disease
    VU0152100 (Standard) is the analytical standard of VU0152100. This product is intended for research and analytical applications. VU0152100 (VU152100) is a highly selective mAChR positive allosteric modulator (permeable to the blood-brain barrier). VU0152100 reverses Amphetamine-induced hypermotility in rats and increased levels of extracellular dopamine in nucleus accumbens and caudate-putamen. VU0152100 has good research potential in psychosis and cognitive impairment associated with mental disorders such as schizophrenia .
    VU0152100 (Standard)
  • HY-W704752
    Z-Doxepin-d3 Hydrochloride

    		Isotope-Labeled Compounds Dopamine Receptor Drug Metabolite Neurological Disease
    Z-Doxepin-d3 hydrochloride is the deuterium labeled 7-Hydroxychlorpromazine hydrochloride (HY-W704749). 7-Hydroxychlorpromazine hydrochloride is the active metabolite of Chlorpromazine (HY-12708). 7-Hydroxychlorpromazine hydrochloride can increase prolactin levels in rats. 7-Hydroxychlorpromazine hydrochloride can increase dopamine turnover and has a sedative effect. In addition, 7-Hydroxychlorpromazine hydrochloride can effectively inhibit amphetamine-induced stereotyped behavior in rats and is used in the study of psychosis .
    Z-Doxepin-d3 Hydrochloride
  • HY-10427A
    iso-WAY-260022

    iso-NRI-022

    		 Serotonin Transporter Dopamine Transporter Cardiovascular Disease
    iso-WAY-260022 (Compound 13R) is an orally active, brain-penetrant and selective norepinephrine transporter (hNET) inhibitor with an IC50 value of 140 nM. iso-WAY-260022 also shows inhibitory effects on human serotonin (hSERT) and dopamine transporters (hDAT). iso-WAY-260022 inhibits norepinephrine reuptake and increases hypothalamic norepinephrine levels to regulate thermoregulatory center function. iso-WAY-260022 is promising for research of vasomotor symptoms, such as menopausal hot flushes, night sweats .
    iso-WAY-260022
  • HY-116062A
    JNJ-7925476

    		Histone Methyltransferase Neurological Disease
    JNJ-7925476 is a triple reuptake inhibitor that selectively and potently inhibits the activity of the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT). JNJ-7925476 is rapidly absorbed into the blood and its concentration in the brain is 7-fold higher than that in plasma. The occupancy ED(50) values of JNJ-7925476 for SERT, NET, and DAT in the rat brain are 0.18, 0.09, and 2.4 mg/kg, respectively. JNJ-7925476 rapidly induces a significant increase in the levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex in a dose-dependent manner. JNJ-7925476 exhibits potent antidepressant-like activity in the mouse tail suspension test. These results suggest that JNJ-7925476 has in vivo efficacy in biochemical and behavioral models of depression .
    JNJ-7925476
  • HY-B1693
    Levomepromazine
    1 Publications Verification

    Methotrimeprazine

    		 5-HT Receptor Dopamine Receptor Histamine Receptor Autophagy Enterovirus Calcium Channel Infection Neurological Disease Inflammation/Immunology
    Levomepromazine (Methotrimeprazine) is an orally active antipsychotic compound and Ca 2+ release inducer. Levomepromazine inhibits SERCA pump and induces an increase in cytoplasmic Ca 2+ levels. Levomepromazine has antagonistic effects on a variety of neurotransmitter receptors, including dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine can induce adaptive ER stress and autophagy. In addition, Levomepromazine has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine can be used in the study psychiatric disorders and relieving nausea and vomiting .
    Levomepromazine
  • HY-B1693R
    Levomepromazine (Standard)

    Methotrimeprazine (Standard)

    		 Reference Standards 5-HT Receptor Dopamine Receptor Autophagy Histamine Receptor Enterovirus Calcium Channel Infection Neurological Disease Inflammation/Immunology
    Levomepromazine (Standard) is the analytical standard of Levomepromazine. This product is intended for research and analytical applications. Levomepromazine (Methotrimeprazine) is an orally active antipsychotic compound and Ca 2+ release inducer. Levomepromazine inhibits SERCA pump and induces an increase in cytoplasmic Ca 2+ levels. Levomepromazine has antagonistic effects on a variety of neurotransmitter receptors, including dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine can induce adaptive ER stress and autophagy. In addition, Levomepromazine has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine can be used in the study psychiatric disorders and relieving nausea and vomiting .
    Levomepromazine (Standard)
  • HY-B1311
    Proadifen hydrochloride
    1 Publications Verification

    SKF-525A; U-5446; RP-5171

    		 Cytochrome P450 Monoamine Oxidase Bcl-2 Family Survivin PARP Neurological Disease Inflammation/Immunology Cancer
    Proadifen (SKF-525A) hydrochloride is a non-competitive Cytochrome P450 inhibitor with an IC50 value of 19 μM. Proadifen hydrochloride reduces monoamine oxidase A (MAO-A) activity and reverses the antidepressantlike behavioral effect of Imipramine (HY-B1490A) and Desipramine (HY-B1272A) in rats. Proadifen hydrochloride also reduces N, N-dimethyltryptamine (DMT) metabolism in liver microsomes and inhibits N-demethylationand Acridone (HY-W007771) formation. Proadifen hydrochloride augments Lipopolysaccharide (LPS) (HY-D1056)-induced fever and exacerbates Prostaglandin E2 (PGE2) (HY-101952) levels in the rat. Proadifen hydrochloride is promising for research of metabolism-related deseases, ovarian carcinoma, inflammation and dopamine neurons-related deseases .
    Proadifen hydrochloride
  • HY-128483
    Fusaric acid

    		TGF-beta/Smad PI3K NF-κB Akt Apoptosis Dopamine β-hydroxylase mTOR Adrenergic Receptor Cardiovascular Disease Endocrinology Cancer
    Fusaric acid is an orally active multi-pathway inhibitor with the activity of inducing oxidative stress and apoptosis. Fusaric acid can chelate divalent metal cations, damage mitochondrial membrane structure, and activate apoptosis-related proteases such as Caspase-3/7, -8, and -9. Fusaric acid also regulates Bax/Bcl-2 protein, inhibits fibrosis-related signaling pathways such as NF-κB, TGF-β1/SMADs, and PI3K/AKT/mTOR, and reduces collagen deposition. Fusaric acid is also a dopamine β-hydroxylase inhibitor, which reduces endogenous levels of norepinephrine and epinephrine in the brain, heart, spleen, and adrenal glands. Fusaric acid can play a role in myocardial fibrosis and improve cardiac hypertrophy in heart disease, and can also be used in the study of esophageal cancer and liver cancer .
    Fusaric acid
  • HY-B1311R
    Proadifen hydrochloride (Standard)

    SKF-525A (Standard); U-5446 (Standard); RP-5171 (Standard)

    		 Reference Standards Cytochrome P450 Monoamine Oxidase Bcl-2 Family Survivin PARP Neurological Disease Inflammation/Immunology Cancer
    Proadifen (hydrochloride) (Standard) is the analytical standard of Proadifen (hydrochloride). This product is intended for research and analytical applications. Proadifen (SKF-525A) hydrochloride is a non-competitive Cytochrome P450 inhibitor with an IC50 value of 19 μM. Proadifen hydrochloride reduces monoamine oxidase A (MAO-A) activity and reverses the antidepressantlike behavioral effect of Imipramine (HY-B1490A) and Desipramine (HY-B1272A) in rats. Proadifen hydrochloride also reduces N, N-dimethyltryptamine (DMT) metabolism in liver microsomes and inhibits N-demethylationand Acridone (HY-W007771) formation. Proadifen hydrochloride augments Lipopolysaccharide (LPS) (HY-D1056)-induced fever and exacerbates Prostaglandin E2 (PGE2) (HY-101952) levels in the rat. Proadifen hydrochloride is promising for research of metabolism-related deseases, ovarian carcinoma, inflammation and dopamine neurons-related deseases [4] .
    Proadifen hydrochloride (Standard)
  • HY-128483R
    Fusaric acid (Standard)

    		TGF-beta/Smad PI3K NF-κB Akt Apoptosis Dopamine β-hydroxylase mTOR Adrenergic Receptor Cardiovascular Disease Endocrinology Cancer
    Fusaric acid (Standard) is the analytical standard of Fusaric acid (HY-128483). This product is intended for research and analytical applications. Fusaric acid is an orally active multi-pathway inhibitor with the activity of inducing oxidative stress and apoptosis. Fusaric acid can chelate divalent metal cations, damage mitochondrial membrane structure, and activate apoptosis-related proteases such as Caspase-3/7, -8, and -9. Fusaric acid also regulates Bax/Bcl-2 protein, inhibits fibrosis-related signaling pathways such as NF-κB, TGF-β1/SMADs, and PI3K/AKT/mTOR, and reduces collagen deposition. Fusaric acid is also a dopamine β-hydroxylase inhibitor, which reduces endogenous levels of norepinephrine and epinephrine in the brain, heart, spleen, and adrenal glands. Fusaric acid can play a role in myocardial fibrosis and improve cardiac hypertrophy in heart disease, and can also be used in the study of esophageal cancer and liver cancer .
    Fusaric acid (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: